Parabilis Medicines, Inc. (PBLS)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
26.85 USD
-2.10
(-7.254%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 4:32 a.m. EDT
Parabilis Medicines presents a catastrophic long-term investment case driven by a complete lack of profitability and unsustainable valuation metrics. The company reports negative earnings per share of -$9.51 and operating margins of -343%, while trading at a price-to-sales ratio of nearly 23,000x—a figure that defies any rational valuation logic for a biotech firm with minimal revenue ($148k). Despite a massive cash hoard relative to debt, the business is burning cash aggressively with no visible path to commercialization or revenue generation that justifies the current market cap. The recent 10% single-day decline and the stock's failure to reclaim its 50-day moving average confirm that the market is actively repricing this speculative asset. Short-term, the heavy put open interest suggests traders are betting on continued weakness or a prolonged consolidation at these depressed levels rather than an imminent catalyst-driven rally. There is no margin of safety here; the valuation gap between the current price and the reality of zero earnings and negligible sales is too wide to ignore. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.117680 |
| AutoARIMA | 0.122089 |
| MSTL | 0.123598 |
| AutoETS | 0.125866 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 2.04 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.130 |
| Excess Kurtosis | -0.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.535 |
| Revenue per Share | 0.015 |
| Market Cap | 3,316,867,584 |
| Forward P/E | -12.28 |
| Website | https://parabilismed.com |
As of Oct. 10, 2026, 4:32 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by significant open interest in out-of-the-money puts (strikes 30, 35, 40) compared to negligible call volume. While there is some call activity at strikes 40 and 45, the overwhelming majority of positioning is defensive, suggesting a belief that the stock will struggle to recover from its recent lows or may face further pressure before any potential rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.083860755 |
| Address1 | 30 Acorn Park Drive |
| All Time High | 42.49 |
| All Time Low | 24.51 |
| Ask | 34.61 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 899,590 |
| Average Daily Volume3 Month | 708,507 |
| Average Volume | 708,507 |
| Average Volume10Days | 899,590 |
| Bid | 20.72 |
| Bid Size | 2 |
| Book Value | 8.482 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.85 |
| Current Ratio | 17.909 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 29.45 |
| Day Low | 26.72 |
| Debt To Equity | 4.535 |
| Display Name | Parabilis Medicines |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | -169,114,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -13.267 |
| Enterprise To Revenue | 15,160.017 |
| Enterprise Value | 2,243,682,560 |
| Eps Current Year | -2.57667 |
| Eps Forward | -2.18667 |
| Eps Trailing Twelve Months | -9.51 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 35.8796 |
| Fifty Day Average Change | -9.0296 |
| Fifty Day Average Change Percent | -0.2516639 |
| Fifty Two Week Change Percent | -8.386076 |
| Fifty Two Week High | 42.49 |
| Fifty Two Week High Change | -15.640001 |
| Fifty Two Week High Change Percent | -0.36808664 |
| Fifty Two Week Low | 24.51 |
| Fifty Two Week Low Change | 2.3400002 |
| Fifty Two Week Low Change Percent | 0.09547124 |
| Fifty Two Week Range | 24.51 - 42.49 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,781,098,200,000 |
| Float Shares | 82,074,249 |
| Forward Eps | -2.18667 |
| Forward P E | -12.278945 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Fullday Change | -2.1000004 |
| Fullday Change Percent | -7.2538867 |
| Fullday Price | 26.85 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -12,951,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07027 |
| Held Percent Institutions | 0.82415 |
| Implied Shares Outstanding | 123,533,240 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-06-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts. |
| Long Name | Parabilis Medicines, Inc. |
| Market | us_market |
| Market Cap | 3,316,867,584 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_316822253 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -231,667,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,555,905,890 |
| Number Of Analyst Opinions | 4 |
| Open | 29.45 |
| Operating Cashflow | -111,291,000 |
| Operating Margins | -343.82434 |
| Phone | (617) 945-9510 |
| Previous Close | 28.95 |
| Price Eps Current Year | -10.420426 |
| Price Hint | 2 |
| Price To Book | 3.1655269 |
| Price To Sales Trailing12 Months | 22,411.268 |
| Profit Margins | 0.0 |
| Quick Ratio | 17.834 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -2.1 |
| Regular Market Change Percent | -7.25389 |
| Regular Market Day High | 29.45 |
| Regular Market Day Low | 26.72 |
| Regular Market Day Range | 26.72 - 29.45 |
| Regular Market Open | 29.45 |
| Regular Market Previous Close | 28.95 |
| Regular Market Price | 26.85 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 1,187,835 |
| Revenue Per Share | 0.015 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 121,952,030 |
| Shares Percent Shares Out | 0.0669 |
| Shares Short | 8,261,483 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,517,704 |
| Short Name | Parabilis Medicines, Inc. |
| Short Percent Of Float | 0.0677 |
| Short Ratio | 7.52 |
| Source Interval | 15 |
| State | MA |
| Symbol | PBLS |
| Target High Price | 45.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 41.75 |
| Target Median Price | 41.0 |
| Total Cash | 1,120,696,960 |
| Total Cash Per Share | 9.072 |
| Total Debt | 47,512,000 |
| Total Revenue | 148,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -9.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.171394 |
| Two Hundred Day Average Change | -6.321394 |
| Two Hundred Day Average Change Percent | -0.19056763 |
| Type Disp | Equity |
| Volume | 1,187,835 |
| Website | https://parabilismed.com |
| Zip | 2,140 |